UBS Group
ARLZ

UBS Group’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

UBS Group’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-8,640
Closed -$3K – 8654
2018
Q2 		$3K Buy
+8,640
New +$7.09K ﹤0.01% 7703
2018
Q1 		– Sell
-4,371
Closed -$6K – 8615
2017
Q4 		$6K Sell
4,371
-11,082
-72% -$18.2K ﹤0.01% 7351
2017
Q3 		$35K Sell
15,453
-109,077
-88% -$146K ﹤0.01% 6063
2017
Q2 		$168K Buy
124,530
+117,910
+1,781% +$170K ﹤0.01% 4848
2017
Q1 		$14K Buy
6,620
+564
+9% +$2.12K ﹤0.01% 6435
2016
Q4 		$26K Buy
6,056
+63
+1% +$299 ﹤0.01% 6367
2016
Q3 		$29K Sell
5,993
-53
-0.9% -$242 ﹤0.01% 5988
2016
Q2 		$20K Buy
6,046
+53
+0.9% +$200 ﹤0.01% 6334
2016
Q1 		$21K Buy
+5,993
New +$30.9K ﹤0.01% 6190

Other funds holding ARLZ

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

UBS Group's ARLZ Position: Q3 2018 in Review

UBS Group sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 8,640 shares — an estimated $3K sold.

UBS Group first reported a position in ARLZ in Q1 2016 and held it in 9 quarters. The position peaked at $168K in Q2 2017. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

  • UBS Group reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • UBS Group sold 8,640 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $3K.
  • UBS Group first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 9 quarters.
  • UBS Group's Aralez Pharmaceuticals Inc. position peaked at $168K in Q2 2017.
  • 4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.